–Alnylamto Webcast its R&D Day Event Today at8:30 am E.T.– CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 13, 2023--Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its ...
Announced pipeline prioritization decisions at 2022 R&D Day, including discontinuation of ALN-XDH in gout and lumasiran in recurrent renal stones, and pausing development of cemdisiran in IgA nephropathy. Additional Business Updates Appointed Carolyn Bertozzi, Ph.D. to its Board of Directors. Also...
参考资料: [1] Alnylam R&D day, day 1. Retrieved December 20, 2020, from https://alnylampharmaceuticalsinc.gcs-web.com/static-files/2263dbc0-a3a8-4304-87d1-ab96467f1444 [2] Alnylam R&D day, day 2. Retrieved December 20, 2020, from https://alnylampharmaceuticalsinc.gcs-web.com/static-...
Full 18-month endpoint and safety results from the HELIOS-A Phase 3 study of vutrisiran in early 2022. In addition, in late 2021, Alnylam intends to: Present a review of its pipeline and platform activities at its upcoming R&D Day be...
Alnylam announces today that it will present a review of its RNAi platform and pipeline progress at a virtual R&D Day on December 13, 2023. Alnylam announces today that results from the KARDIA-1 Phase 2 dose-ranging study of zilebesiran will be presented as a Late-Breaker at the American...